MedTrace Logo

In Vitro Exposure by VR to Enhance Return to Work After Sick Leave Due to Mental Health Related Complaints

NCT06888999 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 118

Last updated 2026-01-09

No results posted yet for this study

Summary

The goal of this pilot randomised controlled trial is to investigate whether in vitro exposure by VR enhances return to work (RTW) in flight cabin crew on sick leave with mental health related complaints. The main research questions are: 1. Does VR enhances time to RTW? 2. Does VR increase self-efficacy and positive cognitions regarding RTW, and decrease job anxiety? Researchers will compare a control group receiving care as usual as provided by the occupational physician and a psychologist to an intervention group receiving care as usual plus (al least) one session with VR-glasses in which participants are virtually exposed to their workplace.

Conditions

  • Return to Work
  • Occupational Stress
  • Self-Efficacy

Interventions

OTHER

In vitro exposure to workplace by VR plus care as usual

During the VR-session, guided by the psychologist, participants are virtually exposed to their workplace using VR glasses. Based on the experience of the participants during the vitual visit to their workplace, the psychologist can adjust the therapy. In addition care as usual is provided (see description active comparator).

OTHER

Care as usual: Guidance from occupational physician and psychologist focused on returning to work

Guidance by the occupational physician and a psychologist from a psychologist practice specialized in counseling cabin crew and guiding them with returning to work.

Sponsors & Collaborators

  • KLM Royal Dutch Airlines

    collaborator UNKNOWN

  • KLM Health Services

    collaborator UNKNOWN

  • Villa Uitzicht

    collaborator UNKNOWN

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    lead OTHER

Principal Investigators

  • Roosmarijn M.C. Schelvis, PhD · Amsterdam UMC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-11-17
Primary Completion
2026-11-30
Completion
2027-03-31

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06888999 on ClinicalTrials.gov